WO2006129594A1 - 核酸含有複合体製剤の製造方法 - Google Patents
核酸含有複合体製剤の製造方法 Download PDFInfo
- Publication number
- WO2006129594A1 WO2006129594A1 PCT/JP2006/310647 JP2006310647W WO2006129594A1 WO 2006129594 A1 WO2006129594 A1 WO 2006129594A1 JP 2006310647 W JP2006310647 W JP 2006310647W WO 2006129594 A1 WO2006129594 A1 WO 2006129594A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- poly
- nucleic acid
- preparation
- containing complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- the present invention relates to a method for producing a nucleic acid-containing complex preparation containing a complex of a polynucleotide and a cationic carrier.
- RNA short interfering RNA
- poly I poly I: C
- pharmaceuticals for example, see Patent Documents:! To 3
- polynucleotides have very low uptake into cells, it is necessary to efficiently exhibit their physiological activity in cells.
- a method of forming a complex of a polynucleotide and a cationic carrier and administering it is known.
- a method for preparing a complex of a polynucleotide and a cationic carrier a method of forming a double strand and mixing the polynucleotide and the cationic carrier is common.
- a complex of a polynucleotide and a cationic carrier prepared by a powerful method generally has a very large particle size of several zm to several hundreds xm. Therefore, a nucleic acid-containing complex preparation containing such a complex cannot be sterilized by filtration, and has problems such as the possibility of embolization of capillaries when intravenously administered to humans. Have.
- the polynucleotide as the main drug is more susceptible to degradation by nucleolytic enzymes and temperature and is preferably more stable.
- Patent Document 1 International Publication No. 99/20283 Pamphlet
- Patent Document 2 Pamphlet of International Publication No.99 / 48531
- Patent Document 3 International Publication No. 2004/106511 Pamphlet
- Patent Document 4 Pamphlet of International Publication No.99 / 61032 Disclosure of the invention
- the main object of the present invention is to provide a method for producing a nucleic acid-containing complex preparation that can be sterilized by filtration and intravenously administered to humans and that can maintain the stability of the polynucleotide. To do.
- the present inventors obtained two single-stranded polynucleotides when producing a nucleic acid-containing complex preparation using two complementary polynucleotides and a cationic carrier. After dissolving in the same solution, the powerful solution and the cationic carrier were mixed and dispersed to find that the above object could be achieved, and the present invention was completed.
- Examples of the present invention include the following (1) and (2).
- a solution containing two polynucleotides that can form a double strand in a single strand in the same solution is mixed with a cationic carrier or a raw material solution before the cationic carrier is formed.
- a method for producing a nucleic acid-containing complex preparation characterized by carrying out a dispersion treatment.
- polynucleotide includes polydioxyribonucleotides and polyribonucleotides.
- Polydeoxyribonucleotides contain oligodeoxyribonucleotides, and polyribonucleotides contain oligoribonucleotides.
- Polyoxyribonucleotides may be partially substituted with carboxynucleotides. A part of the polyribonucleotide may be substituted with deoxyribonucleotide.
- polynucleotide examples include polyinosinic acid (hereinafter referred to as "poly I"), polycytidylic acid (hereinafter referred to as “poly C”), polyadenylic acid, polyuridylic acid, poly (cytidylic acid, uridic acid).
- RNA interference RNA interference (hereinafter ⁇ RN It is possible to raise the sense strand and antisense strand of a double-stranded oligonucleotide capable of exhibiting “Ai”.
- RNA interference RNA interference (hereinafter ⁇ RN It is possible to raise the sense strand and antisense strand of a double-stranded oligonucleotide capable of exhibiting “Ai”.
- RNA interference hereinafter ⁇ RN It is possible to raise the sense strand and antisense strand of a double-stranded oligonucleotide capable of exhibiting “Ai”.
- RNA interference RNA interference
- ⁇ RN RNA interference
- siRNA siRNA
- miRNA microRNA
- shRNA short hairpin RNA
- snRNA small nucleated RNA
- RNAi is obvious to those skilled in the art, but has a sequence complementary to the sense strand or antisense strand of the introduced double-stranded oligonucleotide by introducing the double-stranded oligonucleotide into the cell. This is a phenomenon in which mRNA is specifically degraded, and as a result, synthesis of gene products encoded by powerful mRNA is suppressed.
- the number of bases of the polynucleotide is not particularly limited. For example, 5000 or less is appropriate, and 2 000 or less is preferable.
- the number of bases to be used can be appropriately selected depending on the properties of the polynucleotide.
- the term “oligooxyribonucleotide” and “oligoribonucleotide” means those having a base number of 2 to 99.
- the “number of bases” here refers to the number of bases calculated from the chromatogram peak of the molecular weight standard product and the peak of the chromatogram of the sample by, for example, so-called size exclusion chromatography. That is, it means the number of bases calculated from the maximum frequency of the chromatogram.
- An internal force S in the range of 30 to 2000 is appropriate, and 60 to: an internal force S in the range of 1000 is preferable, and the range of 100 to 500 is more preferable.
- the "polynucleotide” according to the present invention is a sense strand or an antisense strand of a double-stranded oligonucleotide capable of exhibiting RNAi
- the number of bases is suitably within the range of 10-50. Yes, preferably in the range of 12-40, more preferably in the range of 15-30.
- the polynucleotide may be chemically modified in whole or in part.
- Such chemically modified polynucleotides include, for example, partially chemically modified poly I or poly (5-bromocytidylic acid) such as poly (7-diazinosinic acid), poly (2'-azidoinosinic acid), Partly chemically modified poly C such as (2_thiocytidylic acid), poly (cytidine-5'-thiophosphoric acid) can be mentioned.
- partially chemically modified poly I or poly (5-bromocytidylic acid) such as poly (7-diazinosinic acid), poly (2'-azidoinosinic acid), Partly chemically modified poly C such as (2_thiocytidylic acid), poly (cytidine-5'-thiophosphoric acid) can be mentioned.
- at least a part of the sugar component or phosphate backbone constituting the nucleotide may be modified.
- Polynucleotides can be produced by methods known to those skilled in the art. For example, it can be produced by a nucleic acid automatic synthesizer or manually by a solid phase synthesis method or a liquid phase synthesis method by a phosphoramidite method or a triester method. Alternatively, the polynucleotide forming the double strand can be produced by dissociating the double strand by a non-enzymatic treatment in which heating is performed at 60 ° C. or higher or an enzymatic treatment using a helicase or the like.
- the "two polynucleotides" according to the present invention are not particularly limited as long as they can form a double strand, and are, for example, a combination of a polydeoxynucleotide and a polyribonucleotide. May be. Further, the number of bases of the two polynucleotides is not necessarily the same.
- “Can form a double strand” means having a sequence that is complementary to the extent that a double strand can be formed when two polynucleotides are mixed under physiological conditions.
- physiological conditions means conditions adjusted to pH, salt composition, and temperature similar to those in the living body. For example, it can be mentioned that the pH is in the range of 5 to 8 at room temperature and the sodium chloride concentration is 150 mM.
- the "cationic carrier” is not particularly limited as long as it is pharmaceutically acceptable, and includes, for example, 2-0 1 (2-jetylaminoethyl) strength rubamoyl 1, 3-.
- ⁇ 1 Cathodic carrier (hereinafter referred to as “Carrier A”) comprising dioleoylglycerol (hereinafter referred to as “Compound A”) and phospholipid as essential constituents, N_ [l _ (2,3-Geolei mouth Xy) propyl] —N, N, N—trimethylammonium chloride and phospholipid as essential constituents Cationic carrier, Oligofactamine (registered trademark) (manufactured by Invitrogen), Ribofectin (registered) Trademark) (manufactured by Invitrogen), ribofactamine (registered trademark) (manufactured by Invitrogen), lipofectamine 2000 (registered trademark) (manufactured by Invitrogrog) (manufact
- Compound A constituting carrier A is disclosed in WO94 / 19314. Can be synthesized by this method.
- the phospholipid constituting the carrier A is not particularly limited as long as it is a pharmaceutically acceptable phospholipid.
- phosphatidylcholine such as egg yolk phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, sphingomyelin or Examples include lecithin such as egg yolk lecithin and soybean lecithin. Of these, lecithin is particularly preferable.
- Carrier A can be prepared, for example, by mixing compound A and phospholipid and dispersing them in a solution by a conventional method.
- an emulsifying disperser or the like can be used as appropriate.
- a powerful emulsifier / disperser is not particularly limited as long as it is used for pharmaceutical purposes.
- an ultrasonic disperser such as SONIFIER (registered trademark) (manufactured by BRANSON, the same shall apply hereinafter) or a microfluidic device.
- the solvent for dispersing the compound A and the phospholipid is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include electrolytes such as water for injection, distilled water for injection, and physiological saline, Examples of the sugar solution include sugar solutions and maltose solutions.
- Processing conditions, processing time, processing temperature, and the like for dispersion can be selected as appropriate.
- the mixing ratio of compound A and phospholipid (weight of phospholipid Z weight of compound A) used in preparing carrier A is the type of phospholipid used and the nucleic acid-containing complex preparation. Different forces depending on the nature of the two polynucleotides to be mixed with the carrier A, etc. Suitable range is 0.:! ⁇ 10, preferably in the range 0.5-5: more in the range! ⁇ 2 preferable.
- the preparation of the present invention In the nucleic acid-containing complex preparation (hereinafter referred to as "the preparation of the present invention") according to the present invention, after two polynucleotides are dissolved in the same solution, a strong solution and a cationic carrier are dispersed. It can be produced by mixing the solution or the raw material solution before the cationic carrier is formed, and performing a dispersion treatment by a conventional method.
- a dispersion treatment an emulsifying disperser or the like can be used as appropriate.
- a powerful emulsifier / disperser if it is used for medical purposes There is no particular limitation.
- an ultrasonic disperser such as SONIFIER (registered trademark), a microfluidizer (registered trademark), a nanomizer (registered trademark), DeBEE2000 (registered trademark), a finalizer (registered trademark), Nano2000 ( Listed high-pressure emulsifiers such as registered trademark).
- the solvent for dissolving the polynucleotide is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include electrolyte solutions such as water for injection, distilled water for injection, and physiological saline, glucose solution, and maltose solution. And the like.
- Processing conditions, processing time, processing temperature, and the like for dispersion can be selected as appropriate.
- the mixing ratio of the polynucleotide and the cationic carrier (total weight of the polynucleotide / weight of the force thionic carrier) used when producing the preparation of the present invention is determined by the properties of the polynucleotide used and the cationic carrier, etc. Depending on the force, a range of 0.0005 to 1 is appropriate, and a range of 0.001 to 0.4 is preferable. Further, when the cationic carrier is carrier A, an internal force S in the range of 0.0005 to:! Is suitable, an internal force S in the range of 0.001 to 0.4, preferably in the range of 0.01 to 0.2. The inside is more preferable.
- the pharmaceutical preparation of the present invention may optionally contain a pharmaceutically acceptable additive.
- emulsification aids eg, strength prillic acid, strength purine acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, arachidonic acid, docosahexaenoic acid, etc.
- Fatty acids and pharmaceutically acceptable salts thereof albumin, dextran), stabilizers (eg, cholesterol, phosphatidic acid), isotonic agents (eg, sodium chloride salt, glucose, maltose, ratatose, sucrose, Trehalose) and pH adjusters (for example, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, triethanolamine).
- stabilizers eg, cholesterol, phosphatidic acid
- isotonic agents eg, sodium chloride salt, glucose, maltose, ratatose, sucrose, Trehalose
- pH adjusters for example, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, triethanolamine.
- the content of the additive in the preparation of the present invention is suitably 90% by weight or less, preferably 70% by weight or less, more preferably 50% by weight or less.
- the additive can be added in an appropriate step before or after dispersion.
- the dispersion of the present invention can be sterilized by filtration using a 0.2 ⁇ m membrane filter, if necessary, after the dispersion treatment.
- the preparation of the present invention may be a lyophilized preparation.
- Such a freeze-dried preparation can be prepared by freeze-drying the liquid preparation of the present invention by a conventional method. For example, after appropriate sterilization of the liquid preparation of the present invention, a predetermined amount is dispensed into a vial, and pre-freezing is carried out for about 2 hours under a condition of about 40 to -20 ° C.
- ⁇ Primary drying under reduced pressure at 10 ° C, followed by secondary drying under reduced pressure at about 15-25 ° C and lyophilization.
- the inside of the vial can be replaced with nitrogen gas and stoppered to obtain a freeze-dried preparation of the preparation of the present invention.
- the lyophilized preparation of the preparation of the present invention can be used by re-dissolving generally by adding any appropriate solution (re-dissolving solution).
- re-dissolving solution examples include water for injection, physiological saline, and other general infusion solutions.
- the amount of this redissolved solution varies depending on the application and is not particularly limited, but it is suitably 0.5 to 5 times the amount before lyophilization or 500 mL or less.
- the dosage form of the preparation of the present invention is not particularly limited as long as it is a pharmaceutically acceptable dosage form.
- intravenous administration, intraarterial administration, oral administration, intratumoral administration, transdermal administration, mucosal administration, Intrarectal administration may be mentioned. Of these, intravenous administration, transdermal administration, and mucosal administration are particularly preferred.
- it can be administered as a suitable dosage form, for example, various injections, oral preparations, drops, absorbents, eye drops, ointments, lotions, and suppositories.
- this preparation of the present invention was dispensed into vials, and a lyophilized preparation was prepared according to a conventional method.
- the resulting freeze-dried preparation was re-dissolved by adding 8 mL of water for injection.
- a particle size measuring device by a dynamic light scattering method [Nicomp370 (registered trademark): manufactured by Particle Sizing Systems, Inc.]. same as below. ] And it was 152 nm. Also, particles of 1 / im or more were not included.
- this preparation of the present invention was dispensed into vials to prepare a freeze-dried preparation according to a conventional method.
- the resulting freeze-dried preparation was redissolved by adding 5 mL of water for injection.
- the average particle size of the composite particles in the preparation of the present invention after re-dissolution was measured by a particle size measuring device using a dynamic light scattering method and found to be 146 nm. More than 1 / im Particles were not included.
- this preparation of the present invention was dispensed into vials, and a lyophilized preparation was prepared according to a conventional method.
- the resulting freeze-dried preparation was re-dissolved by adding 8 mL of water for injection.
- the average particle size of the composite particles in the preparation of the present invention after re-dissolution was measured by a particle size measuring apparatus using a dynamic light scattering method, it was 142 nm. Also, particles of 1 / im or more were not included.
- Water for injection was added to 12 g of Compound A, 0.2 g of purified egg yolk lecithin and 2 g of maltose to make 10 mL, followed by thorough mixing to obtain a crude dispersion of a cationic carrier.
- the crude dispersion was further subjected to a dispersion treatment at an output of 100 W for 15 minutes using an ultrasonic disperser to obtain 0.32 g of a cationic carrier dispersion.
- 10 mg of Poly I having a base number of about 310 and 10 mg of Poly C having a base number of about 330 were added to 50 mL of water for injection and dissolved.
- Water for injection was added to 12 g of Compound A, 0.2 g of purified egg yolk lecithin and 2 g of maltose to make 10 mL, followed by thorough mixing to obtain a coarse dispersion of a cationic carrier.
- the crude dispersion was further subjected to a dispersion treatment at an output of 100 W for 15 minutes using an ultrasonic disperser to obtain 0.32 g of a cationic carrier dispersion.
- 30 mg of poly I having a base number of about 310 and 30 mg of poly C having a base number of about 330 were added to 10 mL of water for injection and dissolved.
- this preparation of the present invention was dispensed into vials to prepare a freeze-dried preparation according to a conventional method.
- the resulting lyophilized preparation was redissolved by adding 0.87 mL of water for injection.
- the average particle size of the composite particles in the preparation of the present invention after re-dissolution was measured by a particle size measuring device using a dynamic light scattering method, and found to be 163 nm. Also, particles of 1 / im or more were not included.
- N— [1— (2,3-Doleyloxy) propyl] —N, N, N-trimethylammonyl chloride manufactured by Tokyo Chemical Industry Co., Ltd.
- 0.16 g of dioleylphosphatidylethanolamine ( (Nippon Yushi Co., Ltd.) and 2 g of maltose were mixed with water for injection to make 10 mL, and the mixture was mixed well with stirring to obtain a coarse dispersion of a cationic carrier.
- the coarse dispersion was further subjected to a dispersion treatment at an output of 100 W for 15 minutes using an ultrasonic disperser to obtain 0.32 g of a cationic carrier dispersion.
- 0.6 g of Compound A, lg of purified egg yolk lecithin and 10 g of maltose were added to water for injection to make 50 mL, and then stirred well to obtain a crude dispersion of a cationic carrier.
- the crude dispersion was further dispersed for 90 minutes at a treatment pressure of 135 MPa using a high-pressure emulsifying disperser to obtain 1.6 g of a cationic carrier dispersion.
- 25 mg of two oligoribonucleotides having 21 bases and complementary sequences were dissolved in a solution of 5 g maltose to which water for injection was added to 25 mL.
- this preparation of the present invention was dispensed into vials to prepare a freeze-dried preparation according to a conventional method.
- the resulting lyophilized preparation was redissolved by adding 0.87 mL of water for injection.
- the average particle size of the composite particles in the preparation of the present invention after re-dissolution was measured by a particle size measuring apparatus using a dynamic light scattering method, it was 147 nm. Moreover, the above particles were not included.
- an aqueous solution of lOOmL containing 250 mg of poly I having a base number of about 180 and an aqueous solution of lOOmL containing 250 mg of poly C having a base number of about 200 were added simultaneously with stirring.
- the mixture was dispersed for 2 hours at a processing pressure of 108 MPa, and then sterilized by filtration through a membrane filter of 0. to obtain a comparative preparation.
- 2 mL of this comparative preparation was dispensed into vials and made into a freeze-dried product according to a conventional method.
- the resulting freeze-dried preparation was re-dissolved by adding 8 mL of water for injection.
- the average particle size of the composite particles in the comparative preparation after re-dissolution was measured by a particle size measurement device using a dynamic light scattering method, it was 149 nm. Also, particles larger than lzm were not included.
- the stability of poly I and poly C contained in the preparation of the present invention obtained in Example 1 and the comparative preparation obtained in Comparative Example 1 with respect to temperature was determined from changes in the number of bases of poly I and poly C. evaluated.
- each preparation was stored for 2 weeks under conditions of a temperature of 40 ° C. and a relative humidity of 75%, and then degreased using diethyl ether (manufactured by Nacalai Testa Co., Ltd., the same applies hereinafter). Then, size exclusion chromatograph using T SK-Gel G5000PW column (manufactured by Tosohichi Co., Ltd., the same shall apply hereinafter).
- Poly I and Poly C temperatures contained in the preparation of the present invention obtained in Example 2 and Example 3. was evaluated from the change in the number of bases of poly I and poly c.
- each preparation was stored for 6 months under conditions of a temperature of 40 ° C. and a relative humidity of 75%, and then degreased using diethyl ether. Then TSK_Gel G5000PW column
- the stability of the oligoribonucleotide contained in the preparation of the present invention obtained in Example 7 with respect to temperature was evaluated from the change in the number of bases of the oligoribonucleotide.
- each preparation was stored for 6 months under conditions of a temperature of 40 ° C. and a relative humidity of 75%, and then degreased using diethyl ether. Thereafter, the base number of the oligoribonucleotide was calculated by anion exchange chromatography using a DNAPac PA-100 column (manufactured by DIO NEX).
- Example 7 As is apparent from Table 3, the oligoribonucleotide in the preparation of the present invention obtained in Example 7 was stable with respect to temperature without changing its base number before and after storage.
- A431 Changes in pharmacological activity after 6 months of storage of the preparation of the present invention obtained in Example 2 under the conditions of a temperature of 40 ° C. and a relative humidity of 75% are shown in A431, a cell line derived from human squamous cell carcinoma. It was evaluated from the growth inhibitory effect on cells.
- IC is the concentration of poly I and poly C combined.
- Example 2 As is apparent from Table 4, the preparation of the present invention obtained in Example 2 was measured before and after storage.
- the pharmacological activity remained unchanged at 50.
- the presence of two polynucleotides in a nucleic acid-containing complex preparation is determined using the Fluorescence Resonance Energy Transfer (F, “FRET” and Re-J) method. Was evaluated by measuring.
- F, “FRET” and Re-J Fluorescence Resonance Energy Transfer
- the FRET method is a method known to those skilled in the art. Specifically, the relative positional relationship between the excitation energy donor fluorescent molecule and the excitation energy acceptor fluorescent molecule generated by light absorption is measured as a fluorescence signal. It is a method to do.
- Alexa Fluor568 manufactured by Molecular Probes
- fluorescently labeled poly I hereinafter referred to as “fluorinated poly I”
- Alexa Fluor546 manufactured by Molecular Probe
- poly C having about 180 bases to prepare fluorescently labeled poly C
- the evaluation is based on the preparation of the present invention, comparative preparation, positive control sample and each prepared in 1) above.
- the fluorescence intensity of the comparative control sample was measured, and the FRET efficiency was calculated from the measured value.
- the FRET efficiency is the fluorescence intensity of the test sample containing both Fluorescent Poly I and Fluorescent Poly C, and the fluorescence intensity of the control sample of the test sample containing only Fluorescent Poly C. The value divided by 1 is subtracted from 1.
- the distance between poly I and poly C in the formulation of the present invention is shorter than the distance between poly I and poly C in the comparative formulation and in the positive control sample. It was equivalent to the distance between. That is, it was shown that poly I and poly C in the preparation of the present invention are equivalent to the distance between poly I and poly C forming a double chain.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002609032A CA2609032A1 (en) | 2005-05-30 | 2006-05-29 | Method for producing a nucleic-acid-containing complex preparation |
JP2007518962A JP5056413B2 (ja) | 2005-05-30 | 2006-05-29 | 核酸含有複合体製剤の製造方法 |
US11/912,164 US20090069260A1 (en) | 2005-05-30 | 2006-05-29 | Method for producing a nucleic-acid-containing complex preparation |
EP06756692A EP1886688A4 (en) | 2005-05-30 | 2006-05-29 | METHOD FOR PRODUCING PREPARATION OF A NUCLEIC ACID-CONTAINING COMPLEX |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-156622 | 2005-05-30 | ||
JP2005156622 | 2005-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006129594A1 true WO2006129594A1 (ja) | 2006-12-07 |
Family
ID=37481523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/310647 WO2006129594A1 (ja) | 2005-05-30 | 2006-05-29 | 核酸含有複合体製剤の製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090069260A1 (ja) |
EP (1) | EP1886688A4 (ja) |
JP (1) | JP5056413B2 (ja) |
CA (1) | CA2609032A1 (ja) |
WO (1) | WO2006129594A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012029986A1 (ja) | 2010-09-01 | 2012-03-08 | 日本新薬株式会社 | アンチセンス核酸 |
WO2013100190A1 (ja) | 2011-12-28 | 2013-07-04 | 日本新薬株式会社 | アンチセンス核酸 |
EP3514234A1 (en) | 2014-03-12 | 2019-07-24 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid |
WO2020004675A1 (ja) | 2018-06-26 | 2020-01-02 | 日本新薬株式会社 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
WO2020138509A1 (en) | 2018-12-28 | 2020-07-02 | Nippon Shinyaku Co., Ltd. | Myostatin signal inhibitor |
EP3778895A1 (en) | 2015-09-15 | 2021-02-17 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid |
WO2023282346A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 析出抑制剤 |
WO2023282345A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 腎毒性軽減剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE112016003047B4 (de) * | 2015-11-17 | 2022-10-27 | Highlight Therapeutics, S.L. | Neue pharmazeutische zusammensetzung umfassend partikel umfassend einen komplex eines doppelsträngigen polyribonukleotids und eines polyalkylenimins |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994019314A1 (en) | 1993-02-19 | 1994-09-01 | Nippon Shinyaku Co., Ltd. | Glycerol derivative, device and pharmaceutical composition |
WO1999020283A1 (fr) | 1997-10-16 | 1999-04-29 | Nippon Shinyaku Co., Ltd. | Activateur de nuclease de cellules intracancereuses |
WO1999048531A1 (fr) | 1998-03-24 | 1999-09-30 | Nippon Shinyaku Co., Ltd. | Nouveaux remedes contre l'hepatite |
WO1999061032A1 (fr) | 1998-05-25 | 1999-12-02 | Nippon Shinyaku Co., Ltd. | Procede de production d'une preparation composite contenant de l'acide nucleique |
WO2004106511A1 (ja) | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | Bcl−2の発現抑制をするオリゴ二本鎖RNAとそれを含有する医薬組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4388306A (en) * | 1980-06-04 | 1983-06-14 | Merck & Co., Inc. | Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates |
JP2000506865A (ja) * | 1996-03-14 | 2000-06-06 | ジ イミューン リスポンス コーポレイション | インターフェロンをコードする遺伝子の標的を定めた送達 |
US6218112B1 (en) * | 1996-12-23 | 2001-04-17 | Cobra Therapeutics Limited | Optimization of gene delivery and gene delivery system |
EP1547581A1 (en) * | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
-
2006
- 2006-05-29 EP EP06756692A patent/EP1886688A4/en not_active Withdrawn
- 2006-05-29 WO PCT/JP2006/310647 patent/WO2006129594A1/ja active Application Filing
- 2006-05-29 US US11/912,164 patent/US20090069260A1/en not_active Abandoned
- 2006-05-29 CA CA002609032A patent/CA2609032A1/en not_active Abandoned
- 2006-05-29 JP JP2007518962A patent/JP5056413B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994019314A1 (en) | 1993-02-19 | 1994-09-01 | Nippon Shinyaku Co., Ltd. | Glycerol derivative, device and pharmaceutical composition |
WO1999020283A1 (fr) | 1997-10-16 | 1999-04-29 | Nippon Shinyaku Co., Ltd. | Activateur de nuclease de cellules intracancereuses |
WO1999048531A1 (fr) | 1998-03-24 | 1999-09-30 | Nippon Shinyaku Co., Ltd. | Nouveaux remedes contre l'hepatite |
WO1999061032A1 (fr) | 1998-05-25 | 1999-12-02 | Nippon Shinyaku Co., Ltd. | Procede de production d'une preparation composite contenant de l'acide nucleique |
WO2004106511A1 (ja) | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | Bcl−2の発現抑制をするオリゴ二本鎖RNAとそれを含有する医薬組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1886688A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012029986A1 (ja) | 2010-09-01 | 2012-03-08 | 日本新薬株式会社 | アンチセンス核酸 |
WO2013100190A1 (ja) | 2011-12-28 | 2013-07-04 | 日本新薬株式会社 | アンチセンス核酸 |
EP3514234A1 (en) | 2014-03-12 | 2019-07-24 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid |
EP3778895A1 (en) | 2015-09-15 | 2021-02-17 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid |
WO2020004675A1 (ja) | 2018-06-26 | 2020-01-02 | 日本新薬株式会社 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
WO2020138509A1 (en) | 2018-12-28 | 2020-07-02 | Nippon Shinyaku Co., Ltd. | Myostatin signal inhibitor |
WO2023282346A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 析出抑制剤 |
WO2023282345A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 腎毒性軽減剤 |
Also Published As
Publication number | Publication date |
---|---|
US20090069260A1 (en) | 2009-03-12 |
EP1886688A1 (en) | 2008-02-13 |
CA2609032A1 (en) | 2006-12-07 |
JPWO2006129594A1 (ja) | 2009-01-08 |
EP1886688A4 (en) | 2013-01-09 |
JP5056413B2 (ja) | 2012-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5056413B2 (ja) | 核酸含有複合体製剤の製造方法 | |
AU2012330819B2 (en) | Single use system for sterilely producing lipid-nucleic acid particles | |
CN102803284B (zh) | 用于miRNA抑制剂和模拟物的化学修饰基序 | |
JP2020183411A (ja) | 脂質ナノ粒子ホスト中に核酸を封入する方法 | |
CN102231979B (zh) | 基因沉默治疗剂的脂质体有效递送方法和组合物 | |
AU2016372321B2 (en) | Method for preparing polymeric micelle containing anionic drug | |
Biscans et al. | Hydrophobicity of lipid-conjugated siRNAs predicts productive loading to small extracellular vesicles | |
CN105705638B (zh) | 改善的具有高效能的纳米颗粒型寡核苷酸结构及其制备方法 | |
BR112014016562B1 (pt) | Estrutura de oligo-rna de dupla hélice, nanopartícula e método de preparação | |
CN104244987A (zh) | 新型寡核苷酸缀合物及其应用 | |
WO2017177869A1 (zh) | 具有高含量阳性脂质化合物的脂质体制剂及其应用 | |
KR101567108B1 (ko) | 핵산 복합체 및 핵산 송달용 조성물 | |
KR101430773B1 (ko) | 핵산 도입용 조성물 | |
CN1166366C (zh) | 含有核酸的复合物制剂的制备方法 | |
WO2018221649A1 (ja) | Apcsの発現を抑制する核酸 | |
ES2691494T3 (es) | Liposoma para administración tópica y aplicación del mismo | |
JP5808246B2 (ja) | 核酸複合体、及び核酸送達用組成物 | |
WO2018207841A1 (ja) | 複合体、複合体を含むpH感受性組成物、および複合体の製造方法 | |
CN116159145A (zh) | 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007518962 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11912164 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2609032 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006756692 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006756692 Country of ref document: EP |